See more : Unit Corporation (UNTCW) Income Statement Analysis – Financial Results
Complete financial analysis of Cellectar Biosciences, Inc. (CLRB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cellectar Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Phoenix Biotech Acquisition Corp. (PBAXW) Income Statement Analysis – Financial Results
- Healthwell Acquisition Corp. I (HWELW) Income Statement Analysis – Financial Results
- Seya Industries Limited (SEYAIND.NS) Income Statement Analysis – Financial Results
- Taisho Pharmaceutical Holdings Co., Ltd. (TAIPY) Income Statement Analysis – Financial Results
- Ricoh Company, Ltd. (RICO.L) Income Statement Analysis – Financial Results
Cellectar Biosciences, Inc. (CLRB)
About Cellectar Biosciences, Inc.
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -11.00K | 33.33K | 96.31K | 125.97K | 0.00 | 0.00 | 12.58K | 4.96K |
| Cost of Revenue | 192.38K | 238.87K | 227.64K | 207.93K | 189.36K | 82.27K | 1.55M | 356.67K | 362.50K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.54K |
| Gross Profit | -192.38K | -238.87K | -227.64K | -207.93K | -189.36K | -82.27K | -1.55M | -356.67K | -362.50K | 0.00 | 0.00 | 0.00 | -11.00K | 33.33K | 96.31K | 125.97K | 0.00 | 0.00 | 12.58K | 2.42K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 100.00% | 48.85% |
| Research & Development | 27.27M | 19.22M | 17.59M | 10.14M | 9.00M | 6.84M | 9.47M | 4.75M | 5.16M | 5.96M | 6.86M | 5.12M | 3.60M | 3.00M | 8.08M | 14.53M | 17.43M | 6.44M | 1.14M | 261.77K |
| General & Administrative | 10.75M | 9.59M | 6.54M | 5.15M | 5.18M | 4.82M | 4.14M | 4.70M | 3.40M | 3.70M | 4.44M | 3.63M | 0.00 | 2.49M | 2.18M | 2.19M | 2.87M | 2.49M | 0.00 | 0.00 |
| Selling & Marketing | 945.18K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.69M | 9.59M | 6.54M | 5.15M | 5.18M | 4.82M | 4.14M | 4.70M | 3.40M | 3.70M | 4.44M | 3.63M | 2.69M | 2.49M | 2.18M | 2.19M | 2.87M | 2.49M | 1.44M | 365.88K |
| Other Expenses | 0.00 | 0.00 | 6.63K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 38.96M | 28.81M | 24.13M | 15.29M | 14.18M | 11.66M | 13.60M | 9.45M | 8.55M | 9.67M | 11.30M | 8.75M | 6.29M | 5.48M | 10.26M | 16.72M | 20.29M | 8.93M | 2.58M | 627.64K |
| Cost & Expenses | 38.96M | 28.81M | 24.13M | 15.29M | 14.18M | 11.66M | 13.60M | 9.45M | 8.55M | 9.67M | 11.30M | 8.75M | 6.29M | 5.48M | 10.26M | 16.72M | 20.29M | 8.93M | 2.58M | 630.18K |
| Interest Income | 0.00 | 152.52K | 2.28K | 10.90K | 42.71K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00K | 4.50K | 2.42K | 1.01K | 130.61K | 729.92K | 637.75K | 49.88K | 95.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 29.69K | 16.61K | 7.90K | 841.00 | 446.31K | 9.35K | 9.34K | 430.02K | 2.42K | 1.01K | 130.61K | 0.00 | 0.00 | 0.00 | 208.74K |
| Depreciation & Amortization | 192.38K | 238.87K | 227.64K | 207.93K | 189.36K | 82.27K | 1.55M | 356.67K | 362.50K | 367.20K | 424.76K | 497.25K | 584.84K | 35.34K | 32.35K | 16.89K | 15.37K | 9.52K | 3.24K | 2.54K |
| EBITDA | -38.77M | -28.67M | -23.98M | -15.15M | -13.90M | -13.16M | -12.05M | -9.09M | -8.19M | -9.30M | -10.88M | -8.29M | -6.33M | -12.96M | -10.17M | -16.59M | -19.54M | -8.28M | -2.94M | -604.01K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 45,388.96% | -38,876.20% | 2,049.87% | -13,164.56% | 0.00% | 0.00% | -16,968.75% | -12,172.63% |
| Operating Income | -38.96M | -28.81M | -24.13M | -15.29M | -14.18M | -13.33M | -13.60M | -9.45M | -8.76M | -9.89M | -12.40M | -8.75M | -7.04M | -5.45M | -10.17M | -16.59M | -20.29M | -8.93M | -5.09M | -625.22K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 63,979.27% | -16,351.72% | -10,555.25% | -13,170.82% | 0.00% | 0.00% | -40,428.32% | -12,600.14% |
| Total Other Income/Expenses | 917.15K | 152.52K | 8.92K | 196.18K | 85.71K | 91.74K | 38.68K | 3.27M | 3.26M | 1.78M | 522.76K | -42.19K | -1.89M | -7.20M | -12.11M | 139.61K | 737.05K | 382.63K | -487.02K | -190.07K |
| Income Before Tax | -38.04M | -28.66M | -24.12M | -15.09M | -14.09M | -13.24M | -13.56M | -6.18M | -5.50M | -8.11M | -10.78M | -8.80M | -7.75M | -12.65M | -26.28M | -22.96M | -29.72M | -8.55M | -3.16M | -815.29K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 70,469.15% | -37,960.15% | -27,289.52% | -18,227.50% | 0.00% | 0.00% | -25,146.86% | -16,430.57% |
| Income Tax Expense | -60.00K | -60.00K | -152.20K | -337.63K | -218.51K | -1.55M | -38.68K | -3.27M | -3.42M | -1.56M | -522.76K | 9.34K | 1.14M | -7.55M | 12.11M | -139.61K | -737.05K | -643.75K | 487.02K | 0.00 |
| Net Income | -37.98M | -28.60M | -23.97M | -14.76M | -13.87M | -13.24M | -13.56M | -6.18M | -5.50M | -8.11M | -10.78M | -8.80M | -7.44M | 2.10M | -22.27M | -16.45M | -19.56M | -8.29M | -3.05M | -815.29K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 67,594.75% | 6,286.05% | -23,125.72% | -13,059.99% | 0.00% | 0.00% | -24,264.14% | -16,430.57% |
| EPS | -3.11 | -4.05 | -4.32 | -7.45 | -18.08 | -44.70 | -96.66 | -141.54 | -702.78 | -1.77K | -3.86K | -4.28K | -6.21K | -31.02K | -1.01M | -1.18M | -1.63M | -690.50K | -254.45K | -180.51K |
| EPS Diluted | -3.11 | -4.05 | -4.32 | -7.45 | -18.08 | -44.70 | -96.66 | -141.54 | -702.78 | -1.77K | -3.86K | -4.28K | -6.21K | -31.02K | -1.01M | -1.18M | -1.63M | -690.50K | -254.45K | -180.51K |
| Weighted Avg Shares Out | 12.22M | 7.06M | 5.55M | 1.98M | 767.51K | 296.20K | 140.31K | 43.67K | 7.82K | 4.59K | 2.79K | 2.06K | 1.20K | 147.00 | 22.00 | 14.00 | 12.00 | 12.00 | 12.00 | 4.52 |
| Weighted Avg Shares Out (Dil) | 12.22M | 7.06M | 5.55M | 1.98M | 767.51K | 296.20K | 140.31K | 43.67K | 7.82K | 4.59K | 2.79K | 2.06K | 1.20K | 147.00 | 22.00 | 14.00 | 12.00 | 12.00 | 12.00 | 4.52 |
PDC Energy Target of Unusually Large Options Trading (NASDAQ:PDCE)
PDC Energy Inc (NASDAQ:PDCE) was the target of unusually large options trading activity on Tuesday. Traders purchased 2,021 put options on the company. This is an increase of 712% compared to the average daily volume of 249 put options. Several...
Cellectar Biosciences Phase 2 Data In Multiple Myeloma Is Worth A Look
CLRB's CLR131 recorded a 40% ORR in a Phase 2 Multiple Myeloma study (granted 6 of 15 patients). KPTI's Xpovio was approved for Multiple Myeloma with a lower ORR.
Intra-Cellular Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma
Intra-Cellular stock jumps as its bipolar trial delivers positive data. Medtronic moves ahead with heart valve disease trial.
PDC Energy Announces Pricing of $150 Million Tack-On Senior Notes Offering
DENVER, Sep 10, 2020 (GLOBE NEWSWIRE via COMTEX) -- DENVER, Sept. 10, 2020 (GLOBE NEWSWIRE) -- PDC Energy, Inc. ("PDC" or the "Company") (Nasdaq:PDCE) today...
PDC Energy Announces Pricing of $150 Million Tack-On Senior Notes Offering
PDC Energy, Inc. ("PDC" or the "Company") (Nasdaq:PDCE) today announced that it has priced its previously announced public offering of an additional $150
PDC Energy Launches $150 Million Tack-on Senior Notes Offering
DENVER, Sep 10, 2020 (GLOBE NEWSWIRE via COMTEX) -- DENVER, Sept. 10, 2020 (GLOBE NEWSWIRE) -- PDC Energy, Inc. ("PDC" or the "Company") (Nasdaq:PDCE) today...
Synovus Financial Corp Sells 1,626 Shares of PDC Energy Inc (NASDAQ:PDCE)
Synovus Financial Corp cut its holdings in PDC Energy Inc (NASDAQ:PDCE) by 17.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,832 shares...
Contango Oil & Gas: Back To Basics (NYSEMKT:MCF)
Insiders own nearly one-third of the common. The partnership with Brad Juneau is likely to be a core growth area in the future as it was in the past.
Lowest Insider Activity Since January - The Most Important Insider News (July 2020 Update)
Insider activity is very informative to follow as insiders know their company better than anyone else.
Source: https://incomestatements.info
Category: Stock Reports